Effects of Phosphorylation on the Activity, Inhibition and Stability of Carbonic Anhydrases.

carbonic anhydrase inhibition esterase activity human carbonic anhydrase I human carbonic anhydrase II phosphorylation post-translational modifications sulphonamides

Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
25 May 2023
Historique:
received: 06 04 2023
revised: 23 05 2023
accepted: 24 05 2023
medline: 12 6 2023
pubmed: 10 6 2023
entrez: 10 6 2023
Statut: epublish

Résumé

Carbonic anhydrases (CAs) are a metalloenzyme family that have important roles in cellular processes including pH homeostasis and have been implicated in multiple pathological conditions. Small molecule inhibitors have been developed to target carbonic anhydrases, but the effects of post-translational modifications (PTMs) on the activity and inhibition profiles of these enzymes remain unclear. Here, we investigate the effects of phosphorylation, the most prevalent carbonic anhydrase PTM, on the activities and drug-binding affinities of human CAI and CAII, two heavily modified active isozymes. Using serine to glutamic acid (S > E) mutations to mimic the effect of phosphorylation, we demonstrate that phosphomimics at a single site can significantly increase or decrease the catalytic efficiencies of CAs, depending on both the position of the modification and the CA isoform. We also show that the S > E mutation at Ser50 of hCAII decreases the binding affinities of hCAII with well-characterized sulphonamide inhibitors including by over 800-fold for acetazolamide. Our findings suggest that CA phosphorylation may serve as a regulatory mechanism for enzymatic activity, and affect the binding affinity and specificity of small, drug and drug-like molecules. This work should motivate future studies examining the PTM-modification forms of CAs and their distributions, which should provide insights into CA physiopathological functions and facilitate the development of 'modform-specific' carbonic anhydrase inhibitors.

Identifiants

pubmed: 37298228
pii: ijms24119275
doi: 10.3390/ijms24119275
pmc: PMC10253321
pii:
doi:

Substances chimiques

Carbonic Anhydrases EC 4.2.1.1
Carbonic Anhydrase II EC 4.2.1.-
Carbonic Anhydrase Inhibitors 0
Carbonic Anhydrase IX EC 4.2.1.1

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Australian Research Council
ID : DP190103298
Organisme : Australian Research Council
ID : FT200100798

Références

Nat Commun. 2012 Jun 06;3:876
pubmed: 22673903
Cell Cycle. 2005 Jan;4(1):52-6
pubmed: 15655379
Nucleic Acids Res. 2019 Jan 8;47(D1):D451-D458
pubmed: 30380102
Intrinsically Disord Proteins. 2013 Apr 1;1(1):e25068
pubmed: 28516012
ACS Cent Sci. 2019 Feb 27;5(2):308-318
pubmed: 30834319
J Comp Physiol B. 2016 Jan;186(1):111-22
pubmed: 26498599
Pharmacol Rep. 2007 Sep-Oct;59(5):580-7
pubmed: 18048959
Trends Cell Biol. 1998 Apr;8(4):151-7
pubmed: 9695829
Bioorg Med Chem Lett. 2008 Apr 1;18(7):2267-71
pubmed: 18353640
Int J Biol Macromol. 2020 Apr 15;149:443-449
pubmed: 31978481
J Am Soc Mass Spectrom. 1998 Dec;9(12):1248-54
pubmed: 9835071
J Proteome Res. 2013 Jun 7;12(6):2414-21
pubmed: 23312004
Subcell Biochem. 2014;75:349-59
pubmed: 24146387
Curr Top Med Chem. 2007;7(9):825-33
pubmed: 17504127
Sci Rep. 2016 Mar 24;6:23534
pubmed: 27010073
Anal Chem. 2020 Mar 17;92(6):4614-4622
pubmed: 32096628
Chem Rev. 2012 Aug 8;112(8):4421-68
pubmed: 22607219
Oncogene. 2000 May 15;19(21):2628-37
pubmed: 10851062
Nature. 2016 May 25;534(7605):55-62
pubmed: 27251275
Gigascience. 2017 Feb 1;6(2):1-11
pubmed: 28327990
J Biomol Screen. 2006 Oct;11(7):782-91
pubmed: 16858005
Nucleic Acids Res. 2015 Jan;43(Database issue):D512-20
pubmed: 25514926
Chem Biol. 2015 Feb 19;22(2):186-95
pubmed: 25699602
Molecules. 2022 Apr 14;27(8):
pubmed: 35458743
PLoS Comput Biol. 2015 Feb 18;11(2):e1004049
pubmed: 25692714
Bioorg Med Chem. 2013 Mar 15;21(6):1570-82
pubmed: 22607884
Metabolites. 2018 Feb 28;8(1):
pubmed: 29495652
J Mol Biol. 1999 Dec 17;294(5):1351-62
pubmed: 10600390
J Enzyme Inhib Med Chem. 2020 Dec;35(1):1450-1461
pubmed: 32648529
Sci Rep. 2013;3:2658
pubmed: 24029878
J Mass Spectrom. 2009 May;44(5):821-31
pubmed: 19301359
Biochim Biophys Acta. 1992 Aug 21;1122(3):321-6
pubmed: 1354487
Molecules. 2021 Oct 22;26(21):
pubmed: 34770789
Curr Biol. 2000 Jan 27;10(2):R84-7
pubmed: 10662664
Curr Biol. 1995 Jul 1;5(7):747-57
pubmed: 7583121
Biochemistry. 2006 Feb 21;45(7):2414-24
pubmed: 16475831
Nat Rev Drug Discov. 2008 Feb;7(2):168-81
pubmed: 18167490
J Enzyme Inhib Med Chem. 2021 Dec;36(1):561-580
pubmed: 33615947
J Med Chem. 2016 May 12;59(9):4245-56
pubmed: 26700575
Prog Mol Biol Transl Sci. 2012;106:3-32
pubmed: 22340712
Bioorg Med Chem. 2003 May 15;11(10):2241-6
pubmed: 12713833
Curr Protoc Pharmacol. 2013 Mar;Chapter 2:Unit2.9
pubmed: 23456613
J Enzyme Inhib Med Chem. 2015 Dec;30(6):955-60
pubmed: 25775095
J Mol Biol. 1994 Aug 12;241(2):226-32
pubmed: 8057362
BMC Struct Biol. 2007 Jan 09;7:3
pubmed: 17210087
J Mol Biol. 1992 Oct 20;227(4):1192-204
pubmed: 1433293
PLoS One. 2012;7(11):e49063
pubmed: 23139834
J Physiol. 2013 Oct 15;591(20):4963-82
pubmed: 23878365
J Enzyme Inhib Med Chem. 2013 Apr;28(2):231-9
pubmed: 22803676
Nat Methods. 2009 May;6(5):343-5
pubmed: 19363495
Annu Rev Physiol. 1996;58:523-38
pubmed: 8815807

Auteurs

Xiaojing Huang (X)

School of Chemistry, University of New South Wales, Sydney, NSW 2052, Australia.

Daniel Winter (D)

School of Chemistry, University of New South Wales, Sydney, NSW 2052, Australia.

Dominic J Glover (DJ)

School of Biotechnology & Biomolecular Sciences, University of New South Wales, Sydney, NSW 2052, Australia.

Claudiu T Supuran (CT)

Neurofarba Department, Sezione di Scienze Farmaceutiche, Universita degli Studi di Firenze, Via Ugo Schiff 6, Sesto Fiorentino, 50019 Florence, Italy.

William A Donald (WA)

School of Chemistry, University of New South Wales, Sydney, NSW 2052, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH